Last updated: September 23, 2026
Relafen DS is best analyzed as a double-strength nabumetone immediate-release tablet, generally corresponding to the 750 mg strength of Relafen. Nabumetone is a nonsteroidal anti-inflammatory drug approved for osteoarthritis and rheumatoid arthritis. Its original brand, Relafen, has no meaningful remaining brand exclusivity, and the commercial opportunity is primarily in low-cost generic supply, differentiated oral solid dosage forms, and excipient systems that improve manufacturability rather than create strong patent barriers.[1][2]
The strongest commercial strategy is a robust, conventional immediate-release tablet using widely accepted excipients, with optional differentiation through smaller tablets, lactose-free composition, improved swallowing characteristics, packaging, and supply reliability.
What is Relafen DS and which active ingredient does it contain?
Relafen DS refers commercially to a higher-strength formulation of nabumetone. Nabumetone is a nonacidic prodrug that is metabolized to 6-methoxy-2-naphthylacetic acid, the pharmacologically active metabolite responsible for much of its anti-inflammatory activity.[1]
| Attribute |
Relafen DS profile |
| Active ingredient |
Nabumetone |
| Likely strength |
750 mg |
| Dosage form |
Immediate-release oral tablet |
| Therapeutic class |
NSAID |
| Main indications |
Osteoarthritis and rheumatoid arthritis |
| Administration |
Oral |
| Original innovator |
SmithKline Beecham, later associated with GlaxoSmithKline |
| FDA approval |
Relafen NDA approved in 1991 |
| Current competitive status |
Genericized, mature market |
| Primary commercial route |
ANDA, authorized generic, contract manufacturing, or private label |
The term "DS" is not itself a distinct FDA dosage-form category. It is a commercial descriptor that generally means double strength. FDA labeling and generic-market records should be checked against the specific national product because a product sold as Relafen DS outside the United States may not have the same formulation, manufacturer, or regulatory status as the U.S. Relafen product.
What excipients are used in Relafen and what functions do they perform?
Public labeling for Relafen tablets identifies a conventional film-coated tablet platform. Reported inactive ingredients include lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, povidone, colloidal silicon dioxide, magnesium stearate, sodium lauryl sulfate, talc, titanium dioxide, hydroxypropyl methylcellulose, and polyethylene glycol.[1]
| Excipient |
Primary function |
Strategic relevance |
| Lactose monohydrate |
Diluent and compressibility aid |
Low cost and established regulatory history; excludes lactose-intolerant positioning |
| Microcrystalline cellulose |
Diluent and dry binder |
Supports tablet strength and direct compression |
| Croscarmellose sodium |
Superdisintegrant |
Helps achieve rapid tablet breakup despite high drug loading |
| Povidone |
Binder |
Improves granule or tablet cohesion |
| Colloidal silicon dioxide |
Glidant and moisture-control aid |
Improves powder flow and blend uniformity |
| Magnesium stearate |
Lubricant |
Reduces sticking and ejection force; excess can slow dissolution |
| Sodium lauryl sulfate |
Wetting agent |
May improve wetting of hydrophobic drug particles |
| Talc |
Anti-adherent and coating aid |
Reduces sticking and supports coating performance |
| Hypromellose |
Film former |
Provides protective and cosmetic coating |
| Polyethylene glycol |
Plasticizer |
Improves coating flexibility |
| Titanium dioxide |
Opacifier and colorant |
Supports appearance and light protection |
The formulation challenge is not chemical stability alone. The principal development risks are high drug loading, tablet size, powder flow, blend uniformity, lubrication sensitivity, and dissolution consistency. A 750 mg nabumetone tablet can become large if the formulation depends heavily on conventional diluents.
How should an excipient strategy be designed for nabumetone 750 mg?
A commercial formulation should prioritize immediate release, mechanical strength, low tablet mass, and reproducible dissolution.
Direct-compression strategy
A direct-compression formulation can combine nabumetone with microcrystalline cellulose, a superdisintegrant, colloidal silicon dioxide, and magnesium stearate. This approach reduces processing steps and avoids residual moisture from wet granulation.
The main risks are poor blend uniformity, segregation, and inadequate flow. Nabumetone particle-size distribution and surface characteristics should be controlled because the active ingredient represents most of the tablet mass. A coarser excipient fraction can improve flow but may increase segregation. A fine excipient fraction can improve content uniformity while increasing dust and cohesion.
Dry-granulation strategy
Roller compaction can improve flow and compressibility without introducing water. It is suitable when direct compression produces capping, lamination, or unacceptable tablet-weight variability. The process requires control of ribbon density, granule size, and over-lubrication.
Dry granulation may support a smaller tablet than a high-diluent direct-compression design, but it adds equipment and process-validation requirements.
Wet-granulation strategy
Wet granulation can improve uniformity and tablet robustness, particularly where the active ingredient has poor compactibility. It increases development time and introduces drying and residual-moisture controls. For a mature generic product, wet granulation is most attractive when dissolution or mechanical performance cannot be achieved through direct compression or roller compaction.
What formulation patents protect Relafen DS?
No strong, commercially relevant formulation-patent barrier is generally associated with the conventional Relafen or nabumetone immediate-release tablet. The original product's exclusivity was based primarily on the historical drug patent and regulatory exclusivity, both of which have expired.
| IP category |
Relafen DS position |
| Original compound patent |
Expired |
| Original brand formulation protection |
Expired or commercially immaterial |
| Current Orange Book formulation barrier |
No material barrier expected for a conventional generic |
| Method-of-use patents |
No material barrier expected for standard osteoarthritis or rheumatoid arthritis use |
| Manufacturing patents |
Potentially relevant only if a supplier uses a proprietary process |
| New formulation patents |
Possible for modified release, abuse deterrence, dispersions, or combination products |
A new applicant could seek patent protection for a genuinely differentiated product, such as a modified-release tablet, multiparticulate formulation, orally disintegrating tablet, taste-masked product, or low-size high-load composition. A patent on a routine excipient substitution would face substantial validity and obviousness risks.
What is the FDA regulatory and Orange Book status of Relafen DS?
Relafen was approved in the United States through an NDA. Nabumetone generic products are generally submitted through the ANDA pathway, relying on reference-product safety, efficacy, and bioequivalence findings.[2][3]
For a U.S. 750 mg generic, the regulatory package would typically require:
- Demonstration of pharmaceutical equivalence.
- Comparative dissolution testing.
- In vivo bioequivalence where required.
- Stability data under ICH conditions.
- Manufacturing-process validation.
- Control of impurities and degradation products.
- Container-closure qualification.
- Labeling consistent with the reference product.
The Orange Book records patents and exclusivity associated with approved products, but a mature nabumetone tablet product does not present the type of active brand patent estate seen with newer specialty medicines.[3] A Paragraph IV strategy would therefore be commercially relevant only if a later-listed patent covered a specific new formulation, use, or manufacturing process.
When did nabumetone lose exclusivity and what is the generic entry risk?
Nabumetone lost practical exclusivity many years ago. Generic entry risk is therefore high for conventional 500 mg and 750 mg immediate-release tablets.
| Risk factor |
Assessment |
| Compound-patent risk |
Low |
| Conventional formulation-patent risk |
Low |
| Paragraph IV exposure |
Low for standard product; higher only for newly patented variants |
| ANDA development complexity |
Low to moderate |
| Bioequivalence risk |
Manageable but dependent on dissolution and formulation design |
| Price erosion |
High |
| Supply-chain competition |
High |
| Brand substitution risk |
High |
The key barrier is commercial, not legal. Nabumetone is a mature NSAID with multiple generic alternatives. A new entrant must compete on manufacturing cost, contract reliability, product availability, and channel access.
What commercial opportunities exist for Relafen DS?
Low-cost generic supply
The most direct opportunity is a reliable 750 mg generic tablet. Buyers may include wholesalers, regional distributors, hospitals, managed-care suppliers, and private-label pharmaceutical companies.
A low-cost product should use commodity-grade excipients with multiple qualified suppliers. Lactose, microcrystalline cellulose, croscarmellose sodium, povidone, silicon dioxide, and magnesium stearate are broadly available. Dual sourcing is commercially important because excipient shortages can interrupt production even when the active ingredient is available.
Lactose-free formulation
Removing lactose can create a practical product distinction, although it is unlikely to support premium pricing by itself. Suitable alternatives include mannitol, dibasic calcium phosphate, pregelatinized starch, and additional microcrystalline cellulose. The replacement must preserve tablet hardness, disintegration, dissolution, and acceptable tablet size.
A lactose-free product may also simplify positioning for institutions that prefer standardized allergen or excipient policies. Marketing claims must remain consistent with the finished-product composition and applicable regulatory requirements.
Smaller or easier-to-swallow tablet
At 750 mg strength, tablet size is commercially relevant. A high-load formulation using roller compaction, optimized particle engineering, or co-processed excipients could reduce tablet dimensions. A smaller tablet may improve adherence, particularly for older patients using multiple medicines.
This opportunity has practical value but limited patent strength unless supported by a non-obvious composition or manufacturing process with reproducible performance.
Packaging and adherence products
Nabumetone is normally administered once or twice daily depending on the prescribed regimen. Calendar blister packs, unit-dose hospital packaging, and adherence-oriented packaging can create channel differentiation without changing the drug formulation.
These opportunities are more likely to produce procurement advantages than durable product exclusivity.
International and private-label supply
Geographic opportunities are strongest in markets where nabumetone remains prescribed and where generic competition is fragmented. A manufacturer could supply:
- U.S. ANDA products.
- European national or decentralized procedure products.
- Emerging-market dossiers.
- Private-label products for regional distributors.
- Hospital and tender channels.
Excipients must be selected with the target market's permitted-substance lists, nitrosamine controls, elemental-impurity expectations, and documentation requirements in mind.
How does Relafen DS compare with other NSAID products?
| Product |
Active ingredient |
Typical commercial profile |
Relafen DS comparison |
| Relafen DS |
Nabumetone |
Mature oral generic |
Limited IP, low manufacturing complexity |
| Naproxen |
Naproxen |
Large generic market |
More intense price competition |
| Meloxicam |
Meloxicam |
Common once-daily NSAID |
Competes on dosing convenience |
| Celecoxib |
Celecoxib |
COX-2 selective product |
Different safety and positioning profile |
| Diclofenac |
Diclofenac |
Multiple oral and topical forms |
Broader dosage-form competition |
| Etodolac |
Etodolac |
Mature generic NSAID |
Similar low-barrier market |
Nabumetone's opportunity is not based on a novel mechanism or protected delivery system. It depends on dependable supply, competitive cost, acceptable tolerability positioning, and access to generic purchasing channels.
What patent litigation and settlement risks affect Relafen DS?
No major current patent-litigation barrier is expected for a conventional nabumetone 750 mg immediate-release tablet. Historical patent disputes associated with the original product would not ordinarily prevent present-day generic development.
Settlement risk becomes relevant if a company develops a new protected product, including:
- Extended-release nabumetone.
- A fixed-dose combination.
- A new indication.
- A specialty coating or delivery system.
- A formulation with a patented particle-size or dispersion profile.
For the standard product, litigation cost is more likely to arise from manufacturing, antitrust, labeling, trademark, or quality disputes than from active compound patent enforcement.
What is the revenue exposure and investment case?
Revenue exposure is typically modest on a per-unit basis because generic nabumetone is subject to price erosion. The product can still generate attractive returns when it uses existing manufacturing capacity, shares packaging and quality infrastructure, and enters a channel with limited supply.
The strongest investment case has four conditions:
- Existing tablet capacity is available.
- The manufacturer can source nabumetone and excipients at stable cost.
- The applicant has access to a high-volume distributor or tender channel.
- The product avoids avoidable complexity, such as an oversized tablet or fragile coating process.
A standalone investment in a conventional Relafen DS product is less compelling than a portfolio strategy covering several mature NSAIDs or a broader contract-manufacturing platform.
Key Takeaways
- Relafen DS is best treated as a nabumetone 750 mg immediate-release tablet.
- The reference formulation uses standard excipients, including lactose, microcrystalline cellulose, croscarmellose sodium, povidone, silicon dioxide, magnesium stearate, and film-coating agents.
- Compound and conventional formulation exclusivity have expired, leaving low legal barriers to generic entry.
- The principal technical risks are tablet size, flow, blend uniformity, lubrication, mechanical strength, and dissolution.
- Commercial differentiation is strongest through low cost, reliable supply, lactose-free composition, smaller tablets, and packaging.
- A conventional product has limited patent value. New IP would require a genuinely differentiated formulation, delivery system, use, or manufacturing process.
- Revenue potential depends more on manufacturing economics and distribution access than on premium pricing.
FAQs
Is Relafen DS the same as nabumetone 750 mg?
Relafen DS generally refers to the higher-strength nabumetone tablet, commonly 750 mg. Product identity should be confirmed against the applicable national label.
Can nabumetone 750 mg be manufactured without lactose?
Yes. Lactose can be replaced with excipients such as microcrystalline cellulose, mannitol, dibasic calcium phosphate, or pregelatinized starch, subject to dissolution, stability, and tablet-performance testing.
Does nabumetone have an active U.S. compound patent?
The original compound protection for nabumetone has expired. Standard immediate-release generic entry is not generally blocked by the original patent estate.
Is a modified-release nabumetone product patentable?
Potentially, but patentability would depend on novelty, non-obviousness, enablement, and demonstrated technical advantages. Routine excipient substitution would provide a weak basis for protection.
What is the main commercial risk for a Relafen DS generic?
The main risk is price competition combined with limited market growth. Supply reliability, cost control, and channel access are more important than patent exclusivity.
References
- DailyMed. (n.d.). Relafen: Nabumetone tablet, film coated prescribing information. U.S. National Library of Medicine.
- U.S. Food and Drug Administration. (1991). Drugs@FDA: Relafen NDA approval information.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, 44th edition.
- U.S. Food and Drug Administration. (2024). Inactive ingredient database.
- United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary.
